Invictus RG bought a new stake in LivaNova PLC (NASDAQ:LIVN) in the 3rd quarter, Holdings Channel reports. The institutional investor bought 2,283 shares of the company’s stock, valued at approximately $283,000.
A number of other hedge funds have also recently made changes to their positions in LIVN. BlackRock Inc. raised its stake in LivaNova by 7.3% in the 3rd quarter. BlackRock Inc. now owns 5,787,930 shares of the company’s stock valued at $717,530,000 after purchasing an additional 394,915 shares during the last quarter. RTW Investments LP raised its stake in LivaNova by 207.9% in the 2nd quarter. RTW Investments LP now owns 431,000 shares of the company’s stock valued at $43,022,000 after purchasing an additional 291,000 shares during the last quarter. Fisher Asset Management LLC raised its stake in LivaNova by 50.5% in the 3rd quarter. Fisher Asset Management LLC now owns 245,378 shares of the company’s stock valued at $30,420,000 after purchasing an additional 82,378 shares during the last quarter. Redmile Group LLC raised its stake in LivaNova by 15.7% in the 2nd quarter. Redmile Group LLC now owns 599,788 shares of the company’s stock valued at $59,871,000 after purchasing an additional 81,500 shares during the last quarter. Finally, OppenheimerFunds Inc. raised its stake in LivaNova by 5.9% in the 2nd quarter. OppenheimerFunds Inc. now owns 1,279,827 shares of the company’s stock valued at $127,752,000 after purchasing an additional 71,806 shares during the last quarter. 87.53% of the stock is owned by hedge funds and other institutional investors.
LIVN opened at $94.84 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.65 and a quick ratio of 1.21. The stock has a market capitalization of $4.80 billion, a price-to-earnings ratio of 30.79, a price-to-earnings-growth ratio of 3.08 and a beta of 0.85. LivaNova PLC has a 12 month low of $76.14 and a 12 month high of $131.54.
LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, October 31st. The company reported $0.82 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.08). The business had revenue of $272.10 million during the quarter, compared to analysts’ expectations of $275.03 million. LivaNova had a negative net margin of 8.31% and a positive return on equity of 8.77%. The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.83 EPS. As a group, sell-side analysts forecast that LivaNova PLC will post 3.1 EPS for the current fiscal year.
LIVN has been the subject of several analyst reports. BidaskClub downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 18th. Zacks Investment Research downgraded shares of LivaNova from a “buy” rating to a “hold” rating in a research note on Thursday, September 20th. Jefferies Financial Group boosted their target price on shares of LivaNova to $150.00 and gave the company a “buy” rating in a research note on Tuesday, October 2nd. BTIG Research reissued a “hold” rating on shares of LivaNova in a research note on Wednesday, November 21st. Finally, UBS Group initiated coverage on shares of LivaNova in a research note on Tuesday, November 27th. They issued a “neutral” rating and a $105.00 target price for the company. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $122.20.
In other LivaNova news, Director Hugh M. Morrison sold 1,000 shares of LivaNova stock in a transaction dated Monday, November 5th. The stock was sold at an average price of $115.65, for a total value of $115,650.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David S. Wise sold 1,500 shares of LivaNova stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $112.83, for a total value of $169,245.00. The disclosure for this sale can be found here. Insiders sold a total of 8,500 shares of company stock valued at $1,002,355 in the last 90 days. 0.41% of the stock is owned by company insiders.
WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/12/08/invictus-rg-purchases-shares-of-2283-livanova-plc-livn.html.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
See Also: Bull Market
Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN).
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.